WP
ORIC icon

Woodline Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Woodline Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8M Buy
1,247,515
+1,000,981
+406% +$11.4M 0.06% 391
2025
Q4 		$2.02M Hold
246,534
– – 0.01% 768
2025
Q3 		$2.96M Buy
246,534
+2,166
+0.9% +$22.8K 0.01% 671
2025
Q2 		$2.48M Buy
+244,368
New +$1.64M 0.01% 695
2022
Q2 		– Sell
-29,095
Closed -$155K – 861
2022
Q1 		$155K Buy
+29,095
New +$262K ﹤0.01% 559

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Woodline Partners's ORIC Position: Q1 2026 in Review

Woodline Partners increased its Oric Pharmaceuticals (ORIC) stake by 406% in Q1 2026, buying an estimated $11.4M and bringing the position to 1,247,515 shares worth $15.8M. The position accounts for 0.06% of the portfolio, ranked #391.

Woodline Partners first reported a position in ORIC in Q1 2022 and has held it in 5 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Woodline Partners held 1,247,515 shares of Oric Pharmaceuticals worth $15.8M as of Q1 2026.
  • Woodline Partners bought 1,000,981 Oric Pharmaceuticals shares in Q1 2026, an estimated $11.4M.
  • Oric Pharmaceuticals made up 0.06% of Woodline Partners's portfolio in Q1 2026, its #391 holding.
  • Woodline Partners first reported a position in Oric Pharmaceuticals in Q1 2022 and has held it in 5 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.